Pfizer’s phase 2 PHAROS trial of Braftovi plus Mektovi shows sustained long-term survival in patients with advanced lung cancer: New York Wednesday, October 22, 2025, 11:00 Hrs ...
Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback